Emerging roles of PPARs in inflammation and immunity

Nature Reviews Immunology

Volumn 2, Issue 10, 2002, Pages 748-759

  Daynes, Raymond A ^a,b   Jones, Dallas C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRASTERONE; ROSIGLITAZONE; STEROID; CELL RECEPTOR; LIGAND; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; ENZYME REPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNITY; IMMUNOREGULATION; INFLAMMATION; LIPID METABOLISM; MACROPHAGE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ULCERATIVE COLITIS; ANIMAL; B LYMPHOCYTE; BIOLOGICAL MODEL; CHEMISTRY; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; LIGANDS; MODELS, IMMUNOLOGICAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0036779687     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri912     Document Type: Review

References (107)

1. Desvergne, B. & Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev. 20, 649-688 (1999).
2. Clark, R. B. The role of PPARs in inflammation and immunity. J. Leukocyte Biol. 71, 388-400 (2002).
3. Chinetti, G. et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573-25580 (1998).
4. Jones, D. C., Ding, X. & Daynes, R. A. Nuclear receptor peroxisome proliferator-activated receptor-α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepression competent. J. Biol. Chem. 277, 6838-6845 (2002). This paper, together with reference 83, was the first to describe the presence of PPARα in lymphocytes and to establish a role for this nuclear receptor in the regulation of cytokine production by activated T cells.
5. Gosset, P. et al. Peroxisome proliferator-activated receptor-γ activators affect the maturation of human monocyte-derived dendritic cells. Eur. J. Immunol. 31, 2857-2865 (2001). This paper describes a role for PPARγ in the regulation of dendritic-cell maturation, and cytokine and chemokine production.
6. Harris, S. G. & Phipps, R. P. The nuclear receptor PPARγ is expressed by mouse T lymphocytes and PPARγ agonists induce apoptosis. Eur. J. Immunol. 31, 1098-1105 (2001).
7. Alleva, D. G. et al. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-γ counter-regulatory activity by IFN-γ. J. Leukocyte Biol. 71, 677-685 (2002).
8. +/- mice to describe a role for PPARγ in B-cell physiology. It showed that these mice have increased levels of circulating IgG and IgM and are more susceptible to autoimmune diseases.
9. Rotondo, D. & Davidson, J. Prostaglandin and PPAR control of immune-cell function. Immunology 105, 20-22 (2002).
10. 2 induce apoptosis in normal and malignant B-lineage cells. J. Immunol 165, 6941-6948 (2000). This was the first report to describe the presence of PPARγ in B cells.
11. Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990).
12. Corton, J. C., Anderson, S. P. & Stauber, A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Ann. Rev. Pharmacol. Toxicol. 40, 491-518 (2000).
13. Gonzalez, F. J. The role of peroxisome proliferator-activated receptor-α in peroxisome proliferation, physiological homeostasis and chemical carcinogenesis. Adv. Exp. Med. Biol. 422, 109-125 (1997).
14. Dreyer, C. et al. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887 (1992).
15. Laudet, V., Hanni, C., Coll, J., Catzeflis, F. & Stehelin, D. Evolution of the nuclear receptor gene superfamily. EMBO J. 11, 1003-1013 (1992).
16. Miyata, K. S., McCaw, S. E., Marcus, S. L., Rachubinski, R. A. & Capone, J. P. The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo. Gene 148, 327-330 (1994).
17. Tugwood, J. D. et al. The mouse peroxisome proliferator-activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11, 433-439 (1992).
18. Mascaro, C. et al. Characterization of a response element for peroxisomal proliferator-activated receptor (PPRE) in human muscle-type carnitine palmitoyltransferase I. Adv. Exp. Med. Biol. 466, 79-85 (1999).
19. Green, S. & Wahli, W. Peroxisome proliferator-activated receptors: finding the orphan a home. Mol. Cell. Endocrinol. 100, 149-153 (1994).
20. IJpenberg, A., Jeannin, E., Wahli, W. & Desvergne, B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA A functional analysis of the malic enzyme gene PPAR response element. J. Biol. Chem. 272, 20108-20117 (1997).
21. Gervois, P. et al. Fibrates increase human REV-ERBα expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol. Endocrinol. 13, 400-409 (1999).
22. Zhu, Y., Qi, C., Calandra, C., Rao, M. S. & Reddy, J. K. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor-γ. Gene Exp. 6, 185-195 (1996).
23. Zamir, I., Zhang, J. & Lazar, M. A. Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev. 11, 835-846 (1997).
24. Hassig, C. A., Fleischer, T. C., Billin, A. N., Schreiber, S. L. & Ayer, D. E. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 89, 341-347 (1997).
25. Dowell, P. et al. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor-α-interacting protein. J. Biol. Chem. 274, 15901-15907 (1999).
26. Shi, Y., Hon, M. & Evans, R. M. The peroxisome proliferator-activated receptor-δ, an integrator of transcriptional repression and nuclear-receptor signaling. Proc. Natl Acad. Sci. USA 99, 2613-2618 (2002).
27. DiRenzo, J. et al. Peroxisome proliferator-activated receptors and retinoic-acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol. Cell. Biol. 17, 2166-2176 (1997).
28. Dowell, P. et al. p300 functions as a coactivator for the peroxisome proliferator-activated receptor-α. J. Biol. Chem. 272, 33435-33443 (1997).
29. Zhu, Y., Qi, C., Jain, S., Rao, M. S. & Reddy, J. K. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J. Biol. Chem. 272, 25500-25506 (1997).
30. Yuan, C. X., Ito, M., Fondell, J. D., Fu, Z. Y. & Roeder, R. G. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc. Natl Acad. Sci. USA 95, 7939-7944 (1998).
31. Xu, H. E. et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3, 397-403 (1999).
32. Gottlicher, M., Widmark, E., Li, Q. & Gustafsson, J. A. Fatty acids activate a chimera of the clofibric-acid-activated receptor and the glucocorticoid receptor Proc. Natl Acad. Sci. USA 89, 4653-4657 (1992).
33. Kliewer, S. A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor-γ and promotes adipocyte differentiation. Cell 83, 813-819 (1995).
34. 2. A prostaglandin D2 metabolite generated during inflammatory processes. J. Biol. Chem. 277, 10459-10466 (2002).
35. Forman, B. M., Chen, J. & Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl Acad. Sci. USA 94, 4312-4317 (1997).
36. Laffitte, B. A. et al Autoregulation of the human liver X receptor α promoter. Mol. Cell. Biol. 21, 7558-7568 (2001).
37. Leibowitz, M. D. et al. Activation of PPARδ alters lipid metabolism in db/db mice. Fed. Eur. Biochem. Soc. Letts 473, 333-336 (2000).
38. Oliver, W. R. Jr et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc Natl Acad. Sci. USA 98, 5306-5311 (2001).
39. Vosper, H. et al. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J. Biol. Chem. 276, 44258-44265 (2001).
40. Delerive, P., Fruchart, J. C. & Staels, B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169, 453-459 (2001).
41. Poynter, M. E. & Daynes, R. A Peroxisome proliferator-activated receptor-α activation modulates cellular redox status, represses nuclear factor-κB signaling and reduces inflammatory cytokine production in aging J. Biol. Chem. 273, 32833-32841 (1998).
42. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
43. Li, M., Pascual, G. & Glass, C. K. Peroxisome proliferator-activated receptor-γ-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20, 4699-4707 (2000).
44. Delerive, P. et al. Peroxisome proliferator-activated receptor-α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274, 32048-32054 (1999).
45. Delerive, P. et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circulation Res. 65, 394-402 (1999).
46. Delerive, P., Gervois, P., Fruchart, J. C. & Staels, B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J. Biol. Chem. 275, 36703-36707 (2000).
47. Desreumaux, P. et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor-γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193, 827-838 (2001).
48. Tan, N. S. et al. Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes Dev. 15, 3263-3277 (2001).
49. -/- mice to describe a role for PPARα in the regulation of inflammation.
50. Field, C. J., Johnson, I. R. & Schley, P. D. Nutrients and their role in host resistance to infection. J. Leukocyte Biol. 71, 16-32 (2002).
51. Grimble, R. F. Nutritional modulation of immune function. Proc. Nutr. Soc. 60, 389-397 (2001).
52. Spencer, N. F., Poynter, M. E., Hennebold, J. D., Mu, H. H. & Daynes, R. A. Does DHEAS restore immune competence in aged animals through its capacity to function as a natural modulator of peroxisome activities? Ann. NY Acad. Sci. 774, 200-216 (1995).
53. Weksler, M. E. Immune senescence and adrenal steroids: immune dysregulation and the action of dehydroepiandrosterone (DHEA) in old animals. Eur. J. Clin. Pharmacol. 45, S21-S23 (1993).
54. Jump, D. B. & Clarke, S. D. Regulation of gene expression by dietary rat. Ann. Rev. Nutr. 19, 63-90 (1999).
55. Peters, J. M. et al. Peroxisome proliferator-activated receptor-α required for gene induction by dehydroepiandrosterone-3 β-sulfate. Mol. Pharmacol. 50, 67-74 (1996).
56. Staels, B. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790-793 (1998).
57. Jiang, C., Ting, A. T. & Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86 (1998).
58. Kippenberger S. et al. Activators of peroxisome proliferator-activated receptors protect human skin from ultraviolet-B-light-induced inflammation. J. Invest. Dermatol. 117, 1430-1436 (2001).
59. Combs, C. K., Bates, P., Karlo, J. C. & Landreth, G. E. Regulation of β-amyloid-stimulated proinflammatory responses by peroxisome proliferator-activated receptor-α. Neurochem. Int. 39, 449-457 (2001).
60. Gupta, R. A. et al. Activation of peroxisome proliferator-activated receptor γ suppresses nuclear factor-κB-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J. Biol. Chem. 276, 31059-31066 (2001).
61. Willson, T. M., Brown, P. J., Sternbach, D. D. & Henke, B. R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550 (2000).
62. -/- embryonic stem cells to describe PPARγ-independent and -dependant effects on the regulation of gene transcription.
63. 2 in activated murine macrophages. Mol. Cell. Biol. 20, 1692-1698 (2000).
64. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl Acad. Sci. USA 97, 4844-4849 (2000).
65. Rival, Y. et al. PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J. Pharmacol. 435, 143-151 (2002).
66. Michalik, L. et al. Impaired skin-wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J. Cell Biol. 154, 799-814 (2001).
67. Peters, J. M. et al. Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol. 20, 5119-5128 (2000).
68. Li, M. et al. An essential role of the NF-κB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166, 7128-7135 (2001).
69. Komuves, L. G. et al. Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARα activators restores tissue homeostasis. J. Invest. Dermatol. 115, 361-367 (2000).
70. Tsutsumi-Ishii, Y. & Nagaoka, I. NF-κB-mediated transcriptional regulation of human β-defensin-2 gene following lipopolysaccharide stimulation. J. Leukocyte Biol. 71, 154-162 (2002).
71. Wada, A. et al. Helicobacter pylori-mediated transcriptional regulation of the human β-defensin-2 gene requires NF-κB. Cell. Microbiol. 3, 115-123 (2001).
72. Serghides, L. & Kain, K. C. Peroxisome proliferator-activated receptor-γ-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNF-α secretion by monocytes/macrophages J. Immunol. 166, 6742-6748 (2001).
73. Hermanowski-Vosatka, A. et al. PPARα agonists reduce 11β-hydroxysteroid dehydrogenase type 1 in the liver. Biochem. Biophys. Res. Commun. 279, 330-336 (2000).
74. Berger, J. et al. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J. Biol. Chem. 276, 12629-12635 (2001).
75. Yau, J. L. et al. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc. Natl Acad. Sci. USA 98, 4716-4721 (2001).
76. Morton, N. M. et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276, 41293-41300 (2001).
77. Sandeep, T. C. & Walker, B. R. Pathophysiology of modulation of local glucocorticoid levels by 11β-hydroxysteroid dehydrogenases. Trends Endocrinol. Metab. 12, 446-453 (2001).
78. Steinman, R. M., Pack, M. & Inaba, K. Dendritic-cell development and maturation. Adv. Exp. Med. Biol. 417, 1-6 (1997).
79. Mellman, I., Turley, S. J. & Steinman, R. M. Antigen processing for amateurs and professionals. Trends Cell Biol. 8, 231-237 (1998).
80. Faveeuw, C. et al. Peroxisome proliferator-activated receptor-γ activators inhibit interleukin-12 production in murine dendritic cells. Fed. Eur. Biochem. Soc. Letts 486, 261-266 (2000).
81. Yang, X. Y. et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor-γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT. J. Biol. Chem. 275, 4541-4544 (2000). This paper was one of the first to show that the activation of PPARγ regulates T-cell cytokine production through the repression of NFAT.
82. Wang, P. et al. Inhibition of the transcription factors AP-1 and NF-κB in CD4 T cells by peroxisome proliferator-activated receptor-γ ligands. Int. Immunopharmacol. 1, 803-812 (2001).
83. Cunard, R. et al. Regulation of cytokine expression by ligands of peroxisome proliferator-activated receptors. J. Immunol. 168, 2795-2802 (2002).
84. Clark, R. B. et al. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T-cell responses. J. Immunol. 164, 1364-1371 (2000). This paper was the first to show that activation of PPARγ regulates T-cell cytokine production.
85. 2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway. J. Immunol. 168, 1372-1379 (2002).
86. Padilla, J., Leung, E. & Phipps, R. P. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin. Immunol. 103, 22-33 (2002).
87. Yang, X. Y. et al. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor-γ activated by macrophage-derived 12/15-lipoxygenase ligands. J. Biol. Chem. 277, 3973-3978 (2002).
88. Huang, J. T. et al. Interleukin-4-dependent production of PPARγ ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378-382 (1999).
89. + type-1 and type-2 T cells. J. Immunol. 167, 3057-3063 (2001).
90. H1 lineage commitment. Cell 100, 655-669 (2000).
91. van Vollenhoven, R. F. Dehydroepiandrosterone in systemic lupus erythematosus. Rheum. Dis. Clin. North Am. 26, 349-362 (2000).
92. Lucas, J. A., Ahmed, S. A., Casey, M. L. & MacDonald, P. C. Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J. Clin. Invest. 75, 2091-2093 (1985).
93. Karmali, R. A., Hanrahan, R., Volkman, A. & Smith, N. Prostaglandins and essential fatty acids in regulation of autoimmunity and development of antibodies to DNA in NZB × NZW F1 mice. Prog. Lipid Res. 20, 655-661 (1981).
94. Ben-Nathan, D., Padgett, D. A. & Loria, R. M. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J. Med. Microbiol. 48, 425-431 (1999).
95. Rasmussen, K. R. Healey M. C., Cheng, L. & Yang, S. Effects of dehydroepiandrosterone in immunosuppressed adult mice infected with Cryptosporidium parvum. J. Parasitol. 81, 429-433 (1995).
96. Danenberg, H. D., Ben-Yehuda, A., Zakay-Rones, Z. & Friedman, G. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine 13, 1445-1448 (1995).
97. Loria, R. M. & Padgett, D. A. Androstenediol regulates systemic resistance against lethal infections in mice. Ann. NY Acad. Sci. 685, 293-295 (1993).
98. Loria, R. M. & Padgett, D. A. Androstenediol regulates systemic resistance against lethal infections in mice. Archives Virol. 127, 103-115 (1992)
99. Kornbluth, A. What happened to drug trials in ulcerative colitis? Problems, PPARs, placebos and (possible) progress. Am. J. Gastroenterol. 96, 3232-3234 (2001).
100. Lewis, J. D. et al. An open-label trial of the PPAR-γ ligand rosiglitazone for active ulcerative colitis. Am. J. Gastroenterol. 96, 3323-3328 (2001).
101. Tan, M. H. Current treatment of insulin resistance in type-2 diabetes mellitus. Int. J. Clin. Pract. Suppl. 54-62 (2000).
102. Molavi, B., Rasouli, N. & Mehta, J. L. Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box? J. Cardiovasc. Pharmacol. Ther. 7, 1-8 (2002).
103. Robins, S. J. PPARα ligands and clinical trials: cardiovascular risk reduction with fibrates. J. Cardiovasc Risk 8, 195-201 (2001).
104. Palakurthi, S. S., Aktas, H., Grubissich, L. M., Mortensen, R. M. & Halperin, J. A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor-γ and mediated by inhibition of translation initiation. Cancer Res. 61, 6213-6218 (2001).
105. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875 (2001).
106. Tolon, R. M., Castillo, A. I., Jimenez-Lara, A. M. & Aranda, A. Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors. Mol. Cell. Biol. 20, 8793-8802 (2000).
107. Yi, Y. W. et al. Gadd45-family proteins are coactivators of nuclear hormone receptors. Biochem. Biophys. Res. Commun. 272, 193-198 (2000).